

## 2022 ANNUAL REPORT

**SIG/Committee Name:** Response Shift SIG

**Date:** March, 30, 2022

**Co-Chairs:** Richard Skolasky, Gudrun Rohde

**Board Liaison:** Richard Skolasky

**Mission:** The purpose of the response shift interest group is to bring together investigators and clinicians who are interested in the influence of response shift (a change in an individual's values, internal standards, and conceptualization of QOL) on QOL assessments. The ultimate objective is to better understand when and why response shift occurs such that healthcare professionals and researchers using patient reported outcomes across various disciplines can recognize and account for response shift.

**Number of SIG Members:**

| Project/Objective    | Actions/Deliverables  | Methods, Theory or Application Project | Project Chair                     | Project Members  | Timeline                              |
|----------------------|---|--|-----------------------------------|--|---------------------------------------|
| 1. Serie of webinars | Title of the webinars:<br>1.Response Shift: Latent trajectory analysis<br>2.Response Shift: Structural equation modelling (SEM) and item response theory (IRT)<br><br>3. Response Shift: Individualized methods and Patient Generated Index (PGI) | Methods                                | Richard Skolasky and Gudrun Rohde | Rick Sawatzky (1). Mathilde Verdam (2) and Véronique Sebille (2), Nancy Mayo (3) | Three webinars during 2022            |
| 2. Discussion        | ISOQOL Response Shift SIG Discussion Panel  | Theory                                 | Richard Skolasky and Gudrun Rohde | Several RS-SIG members are invited to take part                                  | April – May 2022                      |
| 3. RS - pharma       | Listening to the elephant in the room: Response-shift effects in clinical trials research   | Methods                                | Carolyn E Schwartz                | Carolyn E. Schwartz, I-Chan Huang, Gudrun Rohde, and Richard L. Skolasky         | The paper is submitted to Drug Safety |

**Issues Requiring Board Attention:**

If item 3 includes the SIG or ISOQOL name on it, it needs to go to the Board for review and comment before being published.



## 2022 ANNUAL REPORT